NCT07154563Recruiting
Rapid Assessment of Sentinel Lymph Node Metastasis Status Using a Pan-CK-targeting NIR-II Fluorescent Probe in Breast Cancer
Source: ClinicalTrials.gov · Last updated 4 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Breast malignant tumors are a serious threat to women's health, and the current treatment for breast malignant tumors is still dominated by surgery, but the problems faced by patients after surgery such as edema and tumor recurrence are still relatively common, and the high recurrence rate and the occurrence of postoperative complications are closely related to the removal of metastatic lymph nodes during surgery. Therefore, accurate assessment of sentinel lymph node (SLN) metastases is essential to determine the extent of axillary lymph node dissection (ALND) and minimize complications. In this study, we developed a new technique that can rapidly distinguish between metastatic lymph nodes and normal sentinel lymph nodes (SLNs) in breast cancer patients. Briefly, fresh tissue is incubated with the probe and imaged immediately after intraoperative sentinel lymph node resection to identify the metastatic status of SLN. The accuracy of fluorescence imaging is confirmed by pathological diagnosis.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 27 Aug 2025
- Start date
- Feb 2025
- Primary completion date
- Dec 2026
- Lead sponsor
- Yunnan Cancer Hospital
- Diseases
- Metastatic breast cancer
- NCT number
- NCT07154563
What you commit to
- Study type: Observational
- Planned participants: 60
- From Feb 2025 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients had contraindications to surgery, such as serious cardiopulmonary disease, coagulation dysfunction, etc
Other
- Patients unable to participate in the consent process
Who the study is looking for
- Adult patients between 18-75 years of age
- Patients presenting with a breast nodule or mass presumed to be resectable on pre-operative assessment
- Breast cancer patients who are scheduled to undergo sentinel lymph node biopsy or axillary lymph node dissection;
- Good operative candidate
- Subject capable of giving informed consent and participating in the process of consent
Age in the registry: 18 years to 75 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Yunnan Cancer Hospital, Kunming, Yunnan 650118 Coordinator of this site? Confirm its status | Kunming | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.